Edgewise Therapeutics general counsel Moore sells $219,822 in shares

Edgewise Therapeutics' general counsel, John R. Moore, recently sold 5,016 shares of the company's common stock, totaling around $219,822, on August 12, 2026, according to an SEC filing. The shares were sold at an average price between $43.7985 and $44.5019, falling in the range of $43.22 to $44.55 per share. The sale was made to fulfill tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

The RSUs granted to Moore include 32,500 units that will vest in four annual installments starting August 2027, along with 65,000 stock options that vest monthly over 48 months beginning September 2026. Edgewise Therapeutics has recently acquired a muscular dystrophy business from Servier for $2.65 billion, including an upfront payment and potential additional payments contingent on milestones.

Additionally, the company's shares have gained 212% over the past year, currently trading at $44.17, which some analysts consider slightly overvalued relative to its estimated fair value.